UCL Business, the wholly-owned technology transfer company of UCL, has teamed up with investment group Syncona to create a new biopharmaceutical company called Freeline Therapeutics, which will focus on development and commercialisation of gene therapies for bleeding and other debilitating disorders.
With an investment from Syncona of £25 million in Series A financing and from its base at UCL Royal Free London Hospital, the company will work on gene therapies based on its next-generation adeno-associated virus (AAV) gene therapy platform developed by Amit Nathwani, Professor of Haematology at UCL, the new firm’s chief scientific officer.
AAV is a small virus which infects humans but is not currently known to cause disease, causing a very mild immune response. Properties including its ability to infect both dividing and dormant cells make it an attractive candidate for creating viral vectors for gene therapy.
Freeline’s AAV gene therapy platform builds on the successful haemophilia B Phase I/II trial in which all ten treated haemophilia B patients showed safe, sustained expression of blood clotting Factor IX from a single treatment.
“It is exciting to be building a company on this ground-breaking technology that has the potential to transform the lives of patients with a single administration,” said chairman Chris Hollowood, also a Partner with Syncona LLP.
By Selina McKee
Source: Pharma Times
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
